Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare neurological condition that is primarily characterized by mild to moderate intellectual disability and dystonia of the hands. Other signs and symptoms may include dysarthria, behavioral abnormalities, recurrent seizures and/or an unusual gait (style of walking). Partington syndrome usually occurs in males; when it occurs in females, the signs and symptoms are often less severe. It is caused by changes (mutations) in the ARX gene and is inherited in an X-linked recessive manner. Treatment is based on the signs and symptoms present in each person.
Features include always present findings: Intellectual disability; and common findings: Seizure, Dysarthria, and Focal dystonia. 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Delayed speech and language development, Seizure, Dysarthria |
Arms and legs | 2 | Limb dystonia, Lower limb spasticity |
Muscles | 1 | Flexion contracture |
Head and neck | 1 | Triangular face |
Age of onset: infancy.
ARX encodes aristaless related homeobox (562 aa). Transcription factor. Binds to specific sequence motif 5'-TAATTA-3' in regulatory elements of target genes, such as histone demethylase KDM5C. Positively modulates transcription of KDM5C. Highest expression in Ovary (139.1 TPM) and Brain Anterior cingulate cortex BA24 (11.7 TPM).
Partington syndrome is associated with mutations in the ARX gene on chromosome X.
The ARX protein participates in SLIT2 gene expression is stimulated by ISL1 and Primary multipotent pancreatic progenitor cell produces trunk bipotent pancreatic progenitor cell pathways.
ARX is classified as a druggable target (Transcription Factor category) with score 0.0.
Genetic testing for ARX is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 3 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Partington syndrome.
4 publications have been identified in PubMed for Partington syndrome. Research spans Case Report / Case Series (75%) and Review / Meta-Analysis (25%).
Pichon E (2026). [PMID: 41025404](https://pubmed.ncbi.nlm.nih.gov/41025404/). *Mov Disord Clin Pract*. [Review / Meta-Analysis]
Aristidou C (2025). [PMID: 41153441](https://pubmed.ncbi.nlm.nih.gov/41153441/). *Genes (Basel)*. [Case Report / Case Series]
Han JY (2024). [PMID: 39408661](https://pubmed.ncbi.nlm.nih.gov/39408661/). *Int J Mol Sci*. [Case Report / Case Series]
Mehawej C (2024). [PMID: 39062680](https://pubmed.ncbi.nlm.nih.gov/39062680/). *Genes (Basel)*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 5:45 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Partington syndrome